Secukinumab for treating non-radiographic axial spondyloarthritis – guidance (TA719)

NICE recommend secukinumab as an option, with set restrictions, for active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated CRP or MRI) that is not controlled well enough with NSAIDs and TNF-alpha inhibitors in adults.

SPS commentary:

Treatment should be assessed at 16 weeks, and treatment only continued if there is clear evidence of response, defined as: a reduction in BASDAI score to 50% baseline or by 2 or more units, and a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

Source:

National Institute for Health and Care Excellence